Logo
x

Search

Subscribe Now

Application

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

  • March 23, 2021
BioNTech and Pfizer Report CMA Submission of BNT162b2 to EMA for COVID-19

BioNTech and Pfizer Report CMA Submission of BNT162b2 to EMA for COVID-19

  • December 2, 2020
Merck KGaA Reports EMA's Validation of MAA for Tepotinib to Treat Advanced NSCLC with METex14 Skipping Alterations

Merck KGaA Reports EMA's Validation of MAA for Tepotinib to Treat Advanced NSCLC with METex14 Skipping Alterations

  • November 27, 2020
Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan

Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER...

  • September 2, 2019
Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan

Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan

  • August 1, 2019
ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

  • April 30, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.